Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Debiopharm, S.A."'
Publikováno v:
In European Urology Supplements March 2009 8(4):131-131
Autor:
Christopher J. Lord, Philippe Pasero, Mathieu Rouanne, Roman M. Chabanon, Jean-Charles Soria, Sophie Postel-Vinay
Publikováno v:
Nature Reviews Cancer
Nature Reviews Cancer, Nature Publishing Group, 2021, 21 (11), pp.701-717. ⟨10.1038/s41568-021-00386-6⟩
Nature Reviews Cancer, Nature Publishing Group, 2021, 21 (11), pp.701-717. ⟨10.1038/s41568-021-00386-6⟩
International audience; Immunotherapy has revolutionized cancer treatment and substantially improved patient outcome with regard to multiple tumour types. However, most patients still do not benefit from such therapies, notably because of the absence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85c09da29bd1c5c5398a09854d40546c
https://pubmed.ncbi.nlm.nih.gov/34376827
https://pubmed.ncbi.nlm.nih.gov/34376827
Autor:
Florian Heil, Angelika Lahr, Norbert Wild, Oliver Krieter, Katharina Lechner, Mark M. Kockx, Simona Rossomanno, Suzana Vega Harring, Maria Martinez-Garcia, Christophe Massard, Manuel Hidalgo, Chia-Huey Ooi, Galina Babitzki, Peter Gerber, Christophe Le Tourneau, Alice Julien-Laferriere
Publikováno v:
Translational Oncology
Translational Oncology, Elsevier, 2021, 14 (2), pp.100984. ⟨10.1016/j.tranon.2020.100984⟩
Translational Oncology, Elsevier, 2021, 14 (2), ⟨10.1016/j.tranon.2020.100984⟩
Translational Oncology, Vol 14, Iss 2, Pp 100984-(2021)
Translational Oncology, Elsevier, 2021, 14 (2), pp.100984. ⟨10.1016/j.tranon.2020.100984⟩
Translational Oncology, Elsevier, 2021, 14 (2), ⟨10.1016/j.tranon.2020.100984⟩
Translational Oncology, Vol 14, Iss 2, Pp 100984-(2021)
Highlights • Angiogenesis is critical to the development and survival of solid tumors. • Vanucizumab inhibits both vascular endothelial growth factor and angiopoietin-2. • Vanucizumab exhibits anti-tumor, anti-angiogenic and anti-metastatic eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ede3c26551da25bb87f68efc11ddf03
https://hal.archives-ouvertes.fr/hal-03141470
https://hal.archives-ouvertes.fr/hal-03141470
Autor:
Deghenghi R; Debiopharm S.A., Lausanne, Switzerland.
Publikováno v:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 1988; Vol. 42 (9), pp. 585-8.